Immunotherapy|related biomarkers

Immunotherapy Biomarkers - Cancer Research Institute

biomarkers can provide insights into each patient's individual cancer—its genetic makeup, its behavior, and its interactions with the immune system—which ...

Biomarkers for Immunotherapy: Current Developments and ...

This review focuses on the development of biomarkers for immunotherapy at the soluble, cellular, and genomic levels.

A New Biomarker for Response to Checkpoint Inhibitors - NCI

Mismatch repair deficiency is a biomarker for predicting response to cancer immune checkpoint inhibitors. A new study may explain why it can ...

Defining clinically useful biomarkers of immune checkpoint inhibitors ...

In this Perspective, we critically assess the multiple new static, dynamic and patient-specific biomarkers, highlight the newest consortia and trial efforts.

Predictive biomarkers of immunotherapy response with ... - Nature

Immune-checkpoint inhibitors show promising effects in the treatment of multiple tumor types. Biomarkers are biological indicators used to ...

The role of biomarkers in personalized immunotherapy

We further discuss the role of current biomarkers to predict response and response to immune checkpoint inhibitors and the promise of combination biomarker ...

Predictive Biomarkers for Checkpoint Inhibitor Immune-Related ...

Immune-checkpoint inhibitors (ICIs) are increasingly used in the treatment of cancer, but they cause immune-related adverse events (irAEs) in around 40% of ...

Immune checkpoint inhibitor therapy can cause immune-related adverse reactions, including various organ toxicity.

Biomarkers and computational models for predicting efficacy to ...

Numerous studies have shown that immune checkpoint inhibitor (ICI) immunotherapy has great potential as a cancer treatment, leading to significant clinical ...

The evolving landscape of biomarkers for checkpoint inhibitor ...

Checkpoint inhibitor-based immunotherapies that target cytotoxic T lymphocyte antigen 4 (CTLA4) or the programmed cell death 1 (PD1) pathway have achieved ...

Immunotherapy-related biomarkers: Confirmations and uncertainties

The currently FDA-approved predictive biomarkers, PD-L1, MSI, and TMB, play a key role in patients' selection to be treated with ICI.

Predictive Biomarkers for Immunotherapy in Lung Cancer

Predictive biomarkers for immunotherapy in lung cancer: perspective from the International Association for the Study of Lung Cancer Pathology Committee.

Predictive biomarkers for cancer immunotherapy with immune ...

In this review, we deeply analyze the exploration course and research progress of predictive biomarkers as an adjunctive tool to tumor immunotherapy.

Progresses in biomarkers for cancer immunotherapy - Lin - 2023

This review provides up-to-date information on the evolving field of currently available biomarkers in predicting immunotherapy.

Immunotherapy Biomarkers Archives

This section focuses on the discovery, development and/or clinical significance of biomarkers for immunomodulatory anti-cancer treatments.

Biomarkers for Predicting Response to Immunotherapy with Immune ...

Among the most widely investigated predictive biomarkers for immunotherapy are programmed death-ligand 1 (PD-L1), microsatellite instability/defective mismatch ...

Biomarkers in Precision Cancer Immunotherapy: Promise and ...

Understanding advances in current biomarker design helps to guide appropriate application of immunotherapy.

Advances and prospects of biomarkers for immune checkpoint ...

This review aims to summarize the current knowledge of biomarkers, discuss issues, and further explore future biomarkers.

Identifying baseline immune-related biomarkers to predict clinical ...

A broad understanding of baseline immunity, both in the periphery and in the tumor microenvironment, is needed in order to fully realize the potential of ...

Developing Biomarkers for Immunotherapy - NCI

Identifying biomarkers for cancer immunotherapy is the goal of a new NCI-supported research network. Such markers can help to identify ...